Compare · NVO vs RAPP
NVO vs RAPP
Side-by-side comparison of Novo Nordisk A/S (NVO) and Rapport Therapeutics Inc. (RAPP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and RAPP operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 104.4x RAPP ($1.75B).
- NVO has been more active in the news (8 items in the past 4 weeks vs 4 for RAPP).
- NVO has more recent analyst coverage (25 ratings vs 10 for RAPP).
- Company
- Novo Nordisk A/S
- Rapport Therapeutics Inc.
- Price
- $41.01-4.51%
- $36.76+2.03%
- Market cap
- $183.15B
- $1.75B
- 1M return
- -10.44%
- -
- 1Y return
- -45.66%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 8
- 4
- Recent ratings
- 25
- 10
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest RAPP
- Large owner Third Rock Ventures V, L.P. sold $743,753 worth of shares (18,572 units at $40.05) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Rapport Therapeutics Inc.
- Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
- Truist resumed coverage on Rapport Therapeutics with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Rapport Therapeutics Inc.
- Large owner Third Rock Ventures V, L.P. sold $5,377,323 worth of shares (133,618 units at $40.24) as part of a pre-agreed trading plan (SEC Form 4)
- Large owner Third Rock Ventures V, L.P. sold $11,094,906 worth of shares (276,513 units at $40.12) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Rapport Therapeutics Inc.
- SEC Form 144 filed by Rapport Therapeutics Inc.
- SEC Form 144 filed by Rapport Therapeutics Inc.